This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    A close up image of a microscope
    Clinical trial
    16/02/23

    A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

    This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.

    • Source: ClinicalTrials.gov
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    30/08/24

    The global phase III SOHO-02 trial, is initiated, being an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of BAY 2927088 as first-line therapy in patients with advanced NSCLC with HER-2 mutations

    Bayer announced that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of investigational agent BAY 2927088 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC), whose tumors have activating HER2 mutations

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/01/17

    Second successful Phase III trial ofIDP 118 (halobetasol propionate and tazarotene) lotion to treat plaque psoriasis.- Valeant Pharma International.

    Valeant Pharmaceuticals International, Inc.announced positive results from a second confirmatory pivotal Phase III, multicenter double-blind, randomized, vehicle-controlled clinical study to...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/12/16

    Successful Phase III trial for IDP 118 (halobetasol propionate and tazarotene) to treat plaque psoriasis.-Valeant Pharma Intl.

    Valeant Pharmaceuticals International, Inc. announced positive results from a Phase III, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/04/23

    Additional detailed analyses from Phase II study 201 of lecanemab published as three papers in peer reviewed journals.- Eisai + Biogen

    Eisai Co.,Ltd. and Biogen Inc.announced that three additional detailed analyses from the Phase IIb clinical study

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    19/09/13

    New class of oral treatment for overactive bladder

    Post Hoc Analysis of a Phase III study into the treatment benefits Betmiga� (mirabegron), the first new case of oral...

    Journals
    Journal
    31/01/19

    Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial

    Early everolimus (EVR) introduction and tacrolimus (TAC) minimization after liver transplantation may represent a novel immunosuppressant approach. This phase 2, multicenter, randomized, open-label trial evaluated the...

    • Source: Liver Transplantation
    Journals
    Journal
    01/03/23

    Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

    Background: The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy.

    • Source: Amyloid
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    BMS provides update on phase II study of deucravacitinib in patients with moderate to severe ulcerative colitis.

    Bristol Myers Squibb announced the Phase II LATTICE-UC study evaluating deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared to placebo in moderate to severe ulcerative colitis (UC) did not meet the primary efficacy endpoint of clinical remission at Week 12, nor secondary efficacy endpoint.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/04/12

    MORAb-004 (Morphotek/Eisai) begins Phase II study in metastatic Colorectal Cancer

    A multi-centre Phase II study evaluating the safety and efficacy of MORAb-004, from Morphotek/Eisai, in the treatment of metastatic Colorectal...

    See more